Medibio
Medibio (ASX:MEB) is a small Melbourne-based Australian public company that has historically developed objective diagnostic tests for depression and mental health disorders. The company has 1-10 employees, no active disclosed products or customers, and has sustained operations primarily through equity financings.
- Company typePublic
- Founded1987
- HeadquartersSouth Melbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Medibio does
Medibio (ASX:MEB) is a small, publicly listed Australian company headquartered in Melbourne that has historically positioned itself as a developer of objective diagnostic tests for depression and other mental health disorders, claiming to be the world's first in this category. Founded in 1987, the company operates with 1-10 employees and has sustained itself primarily through episodic equity financings rather than commercial revenue, with no active products, services, or customer relationships disclosed in the available dataset. Between 2012 and 2021, Medibio completed at least six funding rounds totaling over $37M, including two Fidelity-backed raises of $13.5M (2016) and $14M (2017), and acquired Vital Conversations in March 2018 to extend its footprint into mental health conversational/telehealth assets.
The company has no documented products, APIs, integrations, AI modalities, certifications, regulatory milestones, or commercial partnerships in the current dataset. The leadership team consists of CEO Jack Cosentino, CMO Archie Defillo, and CFO Brian L. Mower. The input data also contains a substantial volume of information referencing a separate entity, TrivarX (ASX:TRI), which is developing the Stabl-Im imaging platform for brain cancer using stable isotope labelling combined with MRI; the relationship between Medibio and TrivarX is not explicitly disclosed in the available sources, but the presence of this data suggests a possible strategic pivot, corporate restructuring, or data-mixing artifact that investors should resolve through primary filings before drawing conclusions.
Medibio firmographics
Firmographics- Name
- Medibio
- Legal name
- TrivarX Limited
- Website
- https://medibio.com.au
- Company type
- Public
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medibio (ASX:MEB) is a small Melbourne-based Australian public company that has historically developed objective diagnostic tests for depression and mental health disorders. The company has 1-10 employees, no active disclosed products or customers, and has sustained operations primarily through equity financings.
- Ownership category
- akta.pro rank
Medibio industry classification
Industry- Product category
- Medical Imaging / Biotechnology
- NAICS
- Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)
Keywords
Where Medibio is headquartered
LocationHeadquarters
- HQ city
- South Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Medibio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Medibio product offering
Product offeringCore offering
Medibio (currently operating under the TrivarX corporate identity) is developing Stabl-Im, a proprietary imaging platform that combines stable isotope labelling with MRI to generate additional biological information about brain cancers and metastases without the use of ionising radiation. The platform is being designed to support detection, monitoring, and treatment response assessment for oncology applications, with clinical feasibility study planning underway.
Differentiator
Problem solved
Functional benefit
Products and services
- Stabl-Im Imaging Platform Stabl-Im is Medibio's (TrivarX's) lead imaging program that combines stable isotope labelling with MRI to generate additional biological information about brain cancers and metastases without ionising radiation. It is being designed as a potential complement to existing anatomical and molecular imaging methods for detection, monitoring, and treatment response assessment in oncology.
Quantifiable outcome
- Potential to enable earlier intervention, more informed treatment decisions and improved care for patients
Companies that use Medibio
Customer profileSegments1 record
Ideal customer profiles1 record
Medibio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medibio partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights3 records
Medibio competitors and assessment
Company assessmentEmerging players
- Akili Interactive: Akili developed FDA-cleared digital therapeutics for cognitive and mental health conditions (e.g., ADHD, depression). It represents a digital-measurement/monitoring adjacency to Medibio's diagnostic focus within the broader objective mental health space.
- Mindstrong: Mindstrong (historically) pursued objective, biomarker-based measurement of mental health through smartphone digital phenotyping — a closely adjacent approach to Medibio's objective-diagnostic thesis, although its current operating status is uncertain.
- Big Health: Big Health builds digital therapeutics (e.g., Sleepio, Daylight) for insomnia and anxiety, addressing overlapping mental-health conditions. While therapeutic rather than purely diagnostic, it targets similar payer/employer customers and competes for the same mental-health budget.
- Cerebral: Cerebral is a mental health telehealth and online-prescription platform serving patients with depression, anxiety, and related conditions. It addresses the same end market as Medibio via a different (service-led, prescription-driven) model.
- Talkspace: Talkspace is a publicly listed online therapy platform addressing depression and anxiety. It overlaps with Medibio in mental-health end-market focus and serves as a relevant comparable for a public mental-health pure-play.
- Winterlight Labs: Winterlight Labs analyzes speech and language patterns using AI to detect cognitive and mental health conditions. It is an emerging player with overlapping objective-biomarker methodology targeting CNS indications similar to Medibio's scope.
Direct peers
- Ellipsis Health: Ellipsis Health develops AI-driven voice biomarker technology to objectively detect depression and anxiety, directly mirroring Medibio's objective-diagnostic positioning in mental health. Both companies pursue biomarker-based, non-invasive screening for mood disorders as a core thesis.
- Sonde Health: Sonde Health is a vocal biomarker platform that analyzes voice to detect mental and physical health conditions including depression. It is a direct competitor to Medibio in the objective, biomarker-based mental health diagnostic category.
- Kintsugi: Kintsugi uses voice biomarker AI to identify signs of depression and anxiety from short voice clips. It targets similar customers (health plans, employers, telehealth) and pursues the same objective-mental-health-diagnostic use case as Medibio.
Broad incumbents
- Lyra Health: Lyra Health is a large, well-capitalized mental-health benefits platform serving employers and health plans with therapy, coaching, and digital tools. It is a broader incumbent in the same end market Medibio targets, though its delivery model is service-led rather than diagnostic.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Medibio social profiles
Digital presenceMedibio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medibio leadership team
Management profileNumber of profiles
Profiles4 records
Medibio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medibio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medibio
What does Medibio do?
Medibio (currently operating under the TrivarX corporate identity) is developing Stabl-Im, a proprietary imaging platform that combines stable isotope labelling with MRI to generate additional biological information about brain cancers and metastases without the use of ionising radiation. The platform is being designed to support detection, monitoring, and treatment response assessment for oncology applications, with clinical feasibility study planning underway.
Is Medibio a public or private company?
Medibio is a public company. It is classified as public and is currently operating.
When was Medibio founded?
Medibio was founded in 1987. It employs 11 to 50 people.
Where is Medibio based?
Medibio is headquartered in South Melbourne, Australia, in the Oceania region.
Who are Medibio's main competitors?
Emerging players on record are Akili Interactive, Mindstrong, Big Health, Cerebral, Talkspace and Winterlight Labs. Direct peers are Ellipsis Health, Sonde Health and Kintsugi. Lyra Health is listed as a broad incumbent.
Does Medibio have an API?
No public API is recorded for Medibio.
What industry is Medibio in?
Medibio's product category is Medical Imaging / Biotechnology. Its primary akta.pro industry code is HLALABAK, Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms. Its NAICS code is 5417 and its SIC code is 8000.